Furthermore, MIF levels in lung tissues and BAL fluids were significantly increased in the murine model of bleomycin (BLM)-induced pulmonary fibrosis and chronic treatment with an anti-MIF antibody was reported to have a beneficial effect on lung inflammation in the acute phase, which is the period of 5–10 days after BLM administration [6]. The gene discussed is MIF; the disease is pulmonary fibrosis.